Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Chengjie Cai
Institutions:
China Animal Health and Epidemiology Center,
Innovent Biologics (China)
Observed institutions:
Nanjing Drum Tower Hospital,
China Animal Health and Epidemiology Center,
State Key Laboratory of Pharmaceutical Biotechnology,
Innovent Biologics (China),
Nanjing University
ORCID:
0000-0002-3529-979X
Observed ORCID:
0000-0002-3529-979X
OpenAlex ID:
A5043679370
Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
2023
·
Yuncheng Bei
, Jian He
, et al.
·
Cancer Research
·
31
PDF
Triple signal amplification strategy for the ultrasensitive electrochemical detection of human papillomavirus 16 E6/E7 mRNA
2021
·
Nanfei Yang
, Pei Liu
, et al.
·
Enzyme and Microbial Technology
·
15
Preclinical data of IBI3028, the first clinical-stage bispecific dual-payload ADC, targeting EGFR/c-MET–positive advanced solid tumors.
2026
·
Shi Chen
, Yao Xiong
, et al.
·
Journal of Clinical Oncology
·
1
PDF
Epidemiological Investigation and Partial NS5 Sequence Analysis of Duck Tembusu Virus in Several Regions of China in 2024
2026
·
Wenxin Li
, Yang Li
, et al.
·
Viruses
·
1
PDF
Abstract LB222: Preclinical characterization of IBI3010, a FRα targeting biparatopic antibody-drug conjugate (ADC), for the treatment of FRα expressing tumors
2025
·
Bo Wang
, Jiakai Xing
, et al.
·
Cancer Research
·
1
The first isolation, identification and pathogenicity of a goose-origin duck astrovirus type 3 strain
2026
·
Yang Li
, Chengjie Cai
, et al.
·
Poultry Science
PDF
Supplementary Figures from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
2025
·
Yuncheng Bei
, Jian He
, et al.
Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
2025
·
Yuncheng Bei
, Jian He
, et al.
Supplementary Table S3 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
2025
·
Yuncheng Bei
, Jian He
, et al.
Supplementary Table S1 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
2025
·
Yuncheng Bei
, Jian He
, et al.
Supplementary Table S3 from Targeting CD44 variant 5 with an antibody-drug conjugate is an effective therapeutic strategy for intrahepatic cholangiocarcinoma
2024
·
Yuncheng Bei
, Jian He
, et al.
Supplementary Table 2 from Targeting CD44 variant 5 with an antibody-drug conjugate is an effective therapeutic strategy for intrahepatic cholangiocarcinoma
2024
·
Yuncheng Bei
, Jian He
, et al.
Supplementary Figures from Targeting CD44 variant 5 with an antibody-drug conjugate is an effective therapeutic strategy for intrahepatic cholangiocarcinoma
2024
·
Yuncheng Bei
, Jian He
, et al.
Supplementary Table S1 from Targeting CD44 variant 5 with an antibody-drug conjugate is an effective therapeutic strategy for intrahepatic cholangiocarcinoma
2024
·
Yuncheng Bei
, Jian He
, et al.
Supplementary Table S3 from Targeting CD44 variant 5 with an antibody-drug conjugate is an effective therapeutic strategy for intrahepatic cholangiocarcinoma
2024
·
Yuncheng Bei
, Jian He
, et al.
Supplementary Table 2 from Targeting CD44 variant 5 with an antibody-drug conjugate is an effective therapeutic strategy for intrahepatic cholangiocarcinoma
2024
·
Yuncheng Bei
, Jian He
, et al.
Data from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
2023
·
Yuncheng Bei
, Jian He
, et al.
Supplementary Table S3 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
2023
·
Yuncheng Bei
, Jian He
, et al.
Supplementary Figures from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
2023
·
Yuncheng Bei
, Jian He
, et al.
Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
2023
·
Yuncheng Bei
, Jian He
, et al.
Supplementary Table S1 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
2023
·
Yuncheng Bei
, Jian He
, et al.
Show more works
View as search
Works count:
21
Citation count:
49
H-index:
2
I10-index:
2
Year
Topic
Type